Skip to content

Hypoglycemic Effect Using Ayurveda Treatment Of Sodhan And Shaman Therapy For The Management Of Madhumeha(Obese Diabetic).

A Comparative Clinical Trial On The Efficacy Of Vidangadi Loha And Phalatrikadi Ghanavati With And Without The Prior Administration Of Virechana Karma In Madhumeha (Obese Diabetic).

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/09/046014
Enrollment
110
Registered
2022-09-29
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

None listed

Sponsors

ALL INDIA INSTITUTE OF AYURVEDA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of either gender in the age group of 30-60 years. 2. Patients with classical signs and symptoms of Madhumeha. 3. Patients giving the clinical history of Obese Diabetic (DM Type II). 4. Patients with random blood sugar level (RBS) >200 mg/dl up to 350 mg/dl 5. Fasting blood sugar (FBS) >126 mg/dl up to 250 mg/dl 6. Postprandial blood sugar (PPBS) >140 mg/dl up to 350 mg/dl 7. Glycosylated haemoglobin > 7.5% up to 15% NOTE (In the above-given criteria, there is one should be present and raised HbA1C is necessary.) 8. Sthula Pramehi (Overweight / Obese - BMI >25 g/m2) 9. Newly /early diagnosed cases to be included as per following criteria: i. Patients who are not taking any conventional medicine for more than 3 months, whose sugar levels are raised and fall within the inclusive criteria mentioned above and are willing to take Ayurvedic treatment. ii. Patient accidently diagnosed in routine check-up or when appeared with other complaints in the hospital. iii. Early diagnosed diabetic patients (Maximum 3 years of diabetic history) and not taking any pharmacological drugs since last 3 months.

Exclusion criteria

Exclusion criteria: 1. Patients having insulin dependent DM (type 1) and receiving insulin / OHA 2. Excessive blood glucose: FBS > 250 mg/dl, PPBS > 350 mg/dl, RBS >350 mg/dl and HbA1c >15% 3. Emergency conditions in cases of DM. 4. Patients with acute/chronic liver disease with elevated liver enzymes. 5. Chronic complications like microvascular and macrovascular derangements. 6. Patients reporting to be hypersensitive to any of the proposed trial drugs. 7. Pregnant women/ lactating mothers 8. Participation in other clinical studies in past 12 weeks. 9. Takes psychotropic medications that raise blood glucose (e.g. atypical antipsychotics)

Design outcomes

Primary

MeasureTime frame
1. Blood sugar fasting 2. Post prandial blood sugar level 3. Glycosylated haemoglobin (in %) ââ?¬â?? HbA1C Timepoint: 3 months

Secondary

MeasureTime frame
1. Quality of life 2. Lipid profile 3. Reduction in the classical signs and symptoms of Sthula Pramehi / Madhumeha Urine routine and microscopic examination ââ?¬â?? albumin, sugar, casts/ crystals, epithelial cells, pus cells. Timepoint: 3 months

Countries

India

Contacts

Public ContactKARTAR SINGH BANSAL

All India Institute of Ayurveda

mahtorajaram88@gmail.com8877033663

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026